Health Canada Approves JAMP Pharma's Golimumab Biosimilar PrUpgolyv for Autoimmune Diseases
核心洞察
Health Canada has authorized PrUpgolyv (搜索)™, a golimumab injection biosimilar developed by JAMP Pharma Group (搜索), expanding treatment options for patients with chronic inflammatory autoimmune diseases (搜索).
The approval strengthens JAMP's BioJAMP (搜索)® immunology biosimilars portfolio, which already includes PrSimlandi (搜索)® and PrJamteki (搜索)®, as part of the company's long-term strategy in specialty medicines.
PrUpgolyv (搜索)™ serves as a biosimilar alternative to PrSimponi (搜索)® and will be supported through JAMP Care™ patient support program, offering reimbursement assistance and treatment coordination.
Health Canada has authorized PrUpgolyv (搜索)™ (golimumab injection), a biosimilar developed by JAMP Pharma Group (搜索), marking a significant expansion of treatment options for Canadian patients with chronic inflammatory autoimmune diseases (搜索). The approval, announced on April 20, 2026, reinforces JAMP's position in the Canadian biosimilars market and advances the company's strategic focus on immunology therapeutics.
Strategic Portfolio Expansion
The authorization of PrUpgolyv (搜索)™ represents a biosimilar alternative to PrSimponi (搜索)® and expands BioJAMP (搜索)®'s growing immunology biosimilars portfolio. According to Louis Pilon, President and CEO of JAMP Pharma Group (搜索), "The authorization of PrUpgolyv™ underscores our ambition to build a strong, differentiated immunology portfolio in Canada. Through BioJAMP®, we are investing in biosimilars that expand treatment options while making biologic therapies more accessible for patients and healthcare systems alike."
The new biosimilar complements BioJAMP (搜索)®'s existing immunology portfolio, which includes PrSimlandi (搜索)® and PrJamteki (搜索)®, demonstrating sustained progress in this therapeutic area. Immunology represents a key pillar of JAMP Pharma Group (搜索)'s long-term growth strategy, with the company strategically building a robust pipeline of biosimilars focused on chronic and complex diseases with high unmet medical needs.
Product Specifications and Availability
PrUpgolyv (搜索)™ is available in sterile solution formulations designed for patient convenience:
- 50 mg/0.5 mL prefilled syringes and auto-injectors
- 100 mg/1.0 mL prefilled syringes and auto-injectors
The biosimilar is indicated for the treatment of chronic inflammatory autoimmune diseases (搜索), with complete prescribing information, including contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use available in the product monograph.
Comprehensive Patient Support
JAMP Pharma Group (搜索) will support patients prescribed PrUpgolyv (搜索)™ through JAMP Care™, its comprehensive patient support program. The program is designed to assist both patients and healthcare professionals throughout the treatment journey by offering reimbursement support, onboarding assistance, education resources, and ongoing coordination of care. This initiative reflects JAMP's commitment to reducing barriers to treatment, improving the patient experience, and supporting optimal health outcomes for Canadians living with chronic inflammatory autoimmune diseases (搜索).
Broader Strategic Vision
Beyond immunology, JAMP specialty care is advancing a diversified pipeline of products across oncology, rare diseases and respirology, reflecting the company's ambition to become a leading Canadian provider of complex and specialty medicines. By investing in development capabilities, regulatory expertise, and patient-centric support models, JAMP is positioning itself to deliver future biosimilars that expand treatment choice, strengthen healthcare system sustainability, and improve outcomes for Canadian patients and healthcare professionals.
JAMP Pharma Group (搜索), headquartered in Boucherville in the Greater Montreal area, has experienced exceptional growth over the last 10 years and now offers the largest selection of generic medications in Canada, with nearly 350 molecules. The company operates its own manufacturing plant in Lévis, Québec, which has been operational since 2024, supporting continuous access to quality medications and health solutions for Canadians.